Navigation Links
Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Date:6/2/2008

NEW HAVEN, Conn., June 2 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that data from the Phase III trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in combination with cytarabine in patients with first relapse of acute myelogenous leukemia (AML) had been presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO(R)) in Chicago, Illinois.

The Phase III trial started in March 2005 and was conducted in 69 sites in North America and Europe. In May 2007, after an interim analysis of 210 patients by the trial's data safety monitoring board (DSMB), the Company suspended treatment and enrollment of patients, and the U.S. Food and Drug Administration (FDA) placed the trial on clinical hold, due to increased mortality in the cytarabine plus Cloretazine(R) (VNP40101M) treatment arm of the study, as compared to the cytarabine plus placebo control arm. In January 2008, the Company announced that the FDA had lifted the clinical hold and that a new trial with a lower dose of Cloretazine(R) (VNP40101M) in combination with cytarabine and increased supportive care measures could be pursued in the future.

The objective response rate of the cytarabine and Cloretazine(R) (VNP40101M) treatment arm of the trial was 37% versus 19% for the control arm. The median response duration was 11.2 months on the treatment arm versus 8.1 months on the control arm. Overall survival was 4.2 months on the treatment arm versus 6 months on the control arm.

The Company reported that on-study mortality (deaths from all causes in less than or equal to 30 days or from adverse events in less than or equal to 60 days from any treatment cycle) was 39% for the cytarabine and Cloretazin
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Washington, DC (PRWEB) June 03, 2015 ... Inc. will be honored with a Global Inspire Award ... program recognizes the organization’s outstanding volunteers for their leadership, ... global scale. , The recipients of the ... or group of authors whose article has made a ...
(Date:6/3/2015)... panel of independent experts has spent weeks considering the ... awards presented tonight at TU-Automotive Detroit 2015. , Naturally, ... can now be revealed as: , Car Maker of ... aside by taking the coveted Car Maker of the ... of expert judges., Stand out comments included: , ...
(Date:6/3/2015)... 2015 On Sunday, June 7, 2015, ... gather in their local communities to observe the 28th ... the U.S. and abroad will hold celebrations on this ... the ongoing challenges of cancer survivorship, and to show ... be fruitful, rewarding, and inspiring.,  , National Cancer Survivors ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 DailyEndorphin is ... "events" programming module. With this highly configurable new ... and report on many components of its wellness programming ... no additional charge. , With this new module, annual ... DE challenges, (2) Create participant surveys, (3) Continually report ...
(Date:6/3/2015)... Foot and Ankle Specialists of ... ( Clarksville Division ) was recently presented with ... Advanced Wound Care (SAWC) and the American Podiatric Medical ... The Conference was held on April 29-May 3, ... San Antonio, TX. , Dr. Casey Friske graduated ...
Breaking Medicine News(10 mins):Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 4Health News:TU-Automotive Awards 2015 winners revealed 2Health News:TU-Automotive Awards 2015 winners revealed 3Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 2Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 3Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 4Health News:DailyEndorphin Launches Wellness "Events" Portal 2Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Receives Award at the Spring 2015 Symposium of Advanced Wound Care Conference 2
... WASHINGTONThe World Health Organization released staggering new data about the ... with HIV/AIDS today, in recognition of World TB Day. ... previously thought, the new WHO figures show. In 2007, there ... 15 percent of the total incident cases. That,s double the ...
... Numerous studies have shown a relationship between coping ... breast cancer. In a study published today in the ... an investigation of coping strategies and quality of life ... determines the use of coping strategies. , "It is ...
... "Hangin, Out With My Baby," a CD whose songs ... and toddlers, will be distributed free to new parents in ... Starting today with a live concert at the California Hospital ... away this year by participating hospitals.Arranged and produced by Rod ...
... PHILADELPHIA (March 24, 2009)This month Fox Chase Cancer Center ... using the ViKY system,s revolutionary robotic, compact laparoscope holder. ... of patients in Europe, made its debut in a ... Fox Chase. , "Fox Chase is among ...
... University of Nottingham have shown that an innovative anti-microbial ... life for many community-based dialysis patients. , Results of ... , have shown that the catheter has the potential ... pathogens and protect Continuous Ambulatory Peritoneal Dialysis (CAPD) patients ...
... report released this week by the Government Accountability Office ... and Drug Administration (FDA) and other enforcement agencies that ... paying antidumping duties are also evading U.S. food safety ... voiced concern over the unaddressed problem of illegal shrimp ...
Cached Medicine News:Health News:Alarming new data shows TB-HIV co-infection a bigger threat 2Health News:Quality of life may impact coping strategies of young women with breast cancer 2Health News:Quality of life may impact coping strategies of young women with breast cancer 3Health News:Project 'Hangin' Out With My Baby' Launches National Children's Music Giveaway Campaign at California Hospital Medical Center in Los Angeles 2Health News:Project 'Hangin' Out With My Baby' Launches National Children's Music Giveaway Campaign at California Hospital Medical Center in Los Angeles 3Health News:Fox Chase performs the world’s first successful ViKY robot-assisted surgery for pancreatic tumors 2Health News:Fox Chase performs the world’s first successful ViKY robot-assisted surgery for pancreatic tumors 3Health News:Anti-microbial catheter to cut infection risk for dialysis patients 2Health News:Anti-microbial catheter to cut infection risk for dialysis patients 3Health News:GAO Study Links Duty Circumvention with Evasion of Food Safety Laws 2Health News:GAO Study Links Duty Circumvention with Evasion of Food Safety Laws 3
(Date:6/3/2015)... June 3, 2015 According ... & Peripheral Vascular Devices Market (Embolic Protection, Chronic ... Stent Grafts, IVC Filters, Stents, Balloons and Accessories) ... Interventional Cardiology and Peripheral Vascular Devices Market is ... with a CAGR of 7.4% from 2014 to ...
(Date:6/3/2015)... Pa. , June 3, 2015  Essential Medical, ... that it has been invited to speak at the ... York city on June 4th.  ... Bore closure system, including a review of first in ...    MANTA closes femoral arterial punctures made ...
(Date:6/3/2015)... MARLBOROUGH, Mass. , June 3, 2015 ... RXII ), a biotechnology company focused on ... the areas of dermatology and ophthalmology, today announced ... from the United States Patent and Trademark ... platform (sd‑rxRNA®). The patent, titled "RNA Interference ...
Breaking Medicine Technology:The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 2The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 3The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 4Essential Medical Inc. Announces Participation in 2015 Jefferies Global Healthcare Conference - NYC 2RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye 2RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye 3RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye 4
... To thank customers for their continuous support of our ... beat watches, blood pressure monitors and so on, Shenzhen ... these products with discounts ranging from 65-20%. ... more suitable products to customers, Wuzhou Changlian has introduced ...
... June 8, 2011 Regulus Therapeutics Inc ., ... innovative medicines targeting microRNAs, and Alnylam Pharmaceuticals, Inc. (Nasdaq: ... today announced the publication in Nature ... antagonism of microRNA-103 and microRNA-107 (miR-103/107). Data from a ...
Cached Medicine Technology:Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes 2Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes 3Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes 4Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes 5Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes 6Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes 7
... Medicons osteosynthesis systems for maxillo-facial and ... range of screws and plates for the ... adjusting plates and screws ensure that the ... time. The implants are made from titanium. ...
... Timesh 1.6 Titanium Cranial Fixation Systems ... benefits specifically requested by surgeons and ... cranioplasty implants may be either shaped ... procedure warrants, a pre-measured, cut, bent ...
1.0 mm Micro System. The Titanium Micro System is also useful in the practice of ENT, Neurosurgery and Handsurgery....
... Grafton DBM Matrix PLF ... graft material designed specifically ... Unique trough-like design allows ... allograft/autograft bone. Demineralized bone ...
Medicine Products: